SGEN Stock Rockets As Yet Another Big Pharma Reportedly Considers A Takeover

Pfizer (PFE) is in early talks to acquire cancer specialist Seagen (SGEN), according to a report that sent SGEN stock flying on Monday. X If true, it would help Pfizer add to its lineup of cancer trea...

Pharma companies team up with DeSci to accelerate scientific research

Having emerged as a movement in the research community, Decentralized Science (DeSci) initiatives are progressing at a pace even big pharma cannot ignore. In fact, Pfizer is now the first pharmaceutic...

BudBlockz (BLUNT) and Medibloc (MED) Are Revolutionizing Pharma Sector With Blockchain

Mr. Pratik chadhokar is an Indian Forex, Cryptocurrencies and Financial Market Advisor and analyst with a background in IT and Financial market Strategist. He specialises in market strategies and tech...

This Pharma Is Starting to Recover Nicely

Like so many biopharma stocks, Aurinia Pharmaceuticals (AUPH)  was in need of care over much of 2022. But things are now looking better for the company and the shares have started to rebound. The stoc...

Why Inozyme Pharma (INZY) Shares Are Trading Higher Today

Inozyme Pharma Inc (NASDAQ: INZY) announced topline pharmacokinetic (PK), pharmacodynamic (PD), and safety data from the ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency (P...

DXCM Stock Escalating: Is the Pharma Stock Profitable? 

DXCM surged by 9.99%, and in the last 6 months, the prices of stocks ascended by over 33%.  According to WHO 420 million people globally have Diabetes.  Dexcom, Inc. (NASDAQ: DXCM), founded in 1999 an...

J&J’s upbeat guidance brings good news for big pharma

Johnson & Johnson (NYSE: JNJ), on Tuesday, issued encouraging guidance for the full year. Shares are still trading slightly down this morning.   Why is J&J stock down today? The stock seems to...

Dexcom,Inc. (DXCM): Is the Pharma Stock Profitable?

Registered at 16.27% higher quarterly revenue of $811.79 million.  DXCM is trading premium at a Forward P/E ratio of 101.49. The next earning release is expected to be $0.26, with year-to-year gr...

This Small Pharma Company Could Develop Into a Nice Trade

GlycoMimetics  (GLYC) is a clinical-stage drug developer aiming to create what’s called glycobiology-based therapies for cancers. This one has a catch, however. It’s a small biotech name. ...

‘Pharma Bro’ Shkreli Violated Lifetime Ban And Should Be Sanctioned, FTC Says

Topline The Federal Trade Commission is asking a federal judge to sanction former hedge fund manager Martin Shkreli, arguing he should be held in contempt for violating his lifetime ban from the pharm...

India-Based Sun Pharma Scoops Up Concert Pharmaceuticals For $576M Plus Milestones

Sun Pharmaceutical Industries Limited, India’s top pharmaceutical company, has agreed to acquire Concert Pharmaceuticals Inc (NASDAQ: CNCE) for an upfront payment of $8.00 per share, or $576 mil...

France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline

Ipsen (OTC: IPSEY) has agreed to acquire Albireo Pharma Inc (NASDAQ: ALBO) at $42.00 per share in cash for an initial estimated aggregate consideration of $952 million plus one contingent value right ...

It’s Pharma Time: Why Merck and Lilly Stock Are Buys, but not Pfizer.

My 2023 biotech outlook calls for continued momentum in name changes. I just need to figure out what the stocks will do. Last year, Respira Technologies became Qnovia. It’s run by a former tobacco exe...

Catalyst Pharma Acquires US Rights To Eisai’s Epilepsy Drug

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) agreed to acquire the U.S. rights to Eisai Co Ltd’s (OTC: ESALY) (OTC: ESALF) Fycompa (perampanel) CIII and an exclusive option period to review, eval...

Mark Cuban’s Cost Plus Drugs Expands To Employers In Quest To Disrupt Big Pharma

Topline Billionaire investor Mark Cuban’s self-titled low-cost pharmaceutical company Mark Cuban Cost Plus Drug Company partnered with a major pharmaceutical company this week as the Dallas Mavericks ...

Buy AbbVie Stock. The Pharma Giant Is Still Worth Owning Even as Humira Fades.

Sometimes, a single worry grows so large that it obscures all the good things happening at the same time. That’s the case with the stock of pharma giant AbbVie whose blockbuster drug Humira faces pate...

MRTX Stock Surges On Potential Big Pharma Buyout

A slew of Big Pharma suitors could be looking to buy Mirati Therapeutics (MRTX), according to reports that sent MRTX stock close to a breakout Wednesday. X Bloomberg reported Tuesday that Mirati has d...

CytomX Shares Jump After Cancer Therapy Pact With Pharma Major Regeneron

CytomX Therapeutics Inc (NASDAQ: CTMX) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a collaboration and licensing agreement to create conditionally-activated bispecific cancer therapies....

Big Pharma Stocks Are Breaking Out. Here Are Some Winners.

Big pharma stocks are trying to break out to new heights. They have reported more-than-satisfactory earnings and are expecting further progress on new pipelines of drugs.   These stocks had been outpe...

Two High-Yielding Mid-Cap Spin-Offs On Sale (OGN & VTRS)

As I suspect that many have limited exposure to small- and mid-cap stocks, we’ve updated our special report, Small Companies, Big Potential. Mid-Cap Value Stocks are Attractive Kovitz We also offer a ...

The Race To The Bottom In The Chinese Pharmaceutical Market Reinforces The Need To Market In The United States

while new drugs may be approved in China, unless they have unique mechanisms of action, they may simply join a race to the bottom in terms of domestic reimbursement. Hence the increasing trend for Chi...

Cathie Wood Buys Little-Known Pharma Firm’s Shares for Two Weeks

(Bloomberg) — Cathie Wood has been buying shares of Nurix Therapeutics Inc., a small and relatively little-known biopharmaceutical company, every trading day since Oct. 10. Most Read from Bloomb...

Indian Billionaire Pharma Brothers Get Boost From Their Go-To Pandemic Drug

This story appears in the October 2022 issue of Forbes Asia. Subscribe to Forbes Asia Dilip Surana Courtesy of Dilip Surana This story is part of Forbes’ coverage of India’s Richest 2022. See the full...

With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma

TipRanks Morgan Stanley Says These 3 Reliable Dividend Stocks Should Be on Your Buy List (Especially Right Now) The major investment bank Morgan Stanley has been sounding alerts about the increasingly...

‘Pharma Bro’ Shkreli Plots Post-Jail NYC Return—Seeks Home In ‘Dope Building With Sick Views’

Topline ‘Pharma Bro’ Martin Shkreli, a former hedge fund manager who was convicted of securities fraud in 2017 and released from prison this past May, has made a big re-emergence on social media in re...

Shanghai-Based Pharma Business Breaks Ground On Delaware Facility

WuXi AppTec Chairman Ge Li, back in 2008. Photographer: Ariana Lindquist/Bloomberg News Ariana Lindquist 2008 WuXi STA, a contract research, development, and manufacturing service provider to the phar...

Pharma stocks crater as investors brace for litigation charges

Shares of GSK, Sanofi and Haleon all sold off sharply this week, shedding tens of billions in market value, amid investor fear over potential U.S. litigation charges focused on popular heartburn drug ...

“Pharma Bro” Martin Shkreli Trolls Crypto Twitter

Alex Dovbnya Notorious former pharmaceutical executive pretended to pitch his new crypto start-up to fake 3AC account Former pharmaceutical executive Martin Shkreli caused a stir earlier today after p...

Fosun Pharma Shares Gain After Tie-Up With New Covid Drug Supplier Genuine Biotech

A silhouette of hands in medical gloves hold a medical syringe and a vial in front of Fosun Pharma’s … [+] logo. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Imag...

TYME Technologies Shares Surge On Merger Agreement With Syros Pharma

Motley Fool 3 Dow Stocks That Are Screaming Buys in July For well over a century, the iconic Dow Jones Industrial Average (DJINDICES: ^DJI) has been the most-watched stock index in the world. Original...

‘Pharma Bro’ Martin Shkreli Is Not Launching a DEX—But Says He’s Working on Blockchain Software

Martin Shkreli refuted a press release claiming he was launching a DEX to compete with Uniswap—but says he’s working on something else in crypto. By Tim Hakki, Stacy Elliott and Daniel Roberts J...

Martin Shkreli, former Pharma Bro, Launches a DEX called Albumswap

Martin Shkreli, detested pharma bro, is now a crypto bro. This is according to a press release he issued on behalf of his new foray into the crypto world. According to the press release, the former ja...